Answer
Nivolumab + relatlimab is contraindicated in people with hypersensitivity to either active substance or any of its excipients.
Sources for this answer
- Opdualag 240 mg/80 mg concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.3 Contraindications · Version 6Document updated
Sources checked